FDA Advances New Treatments for Alzheimer’s and Narcolepsy

The U.S. Food and Drug Administration has accepted an investigational new drug application for a Phase 2 Alzheimer’s cognition trial while also approving a novel narcolepsy therapy that targets the underlying disease mechanism. These regulatory moves mark significant progress in developing targeted neurological treatments.